SightfileU.S. market data from official filings

Companies › PHAT

PHATHOM PHARMACEUTICALS INC (PHAT)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001783183 · EDGAR filings · Updated 2026-07-20

PHATHOM PHARMACEUTICALS INC (PHAT) has reported institutional ownership of 86.4%, with 174 institutional managers holding positions valued at $763.6M per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Institutional ownership
86.4%
Institutional managers
174
Reported 13F value
$763.6M
Insider activity
47 trans.
$173.3K net buying
Data flags
1 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, PHATHOM PHARMACEUTICALS INC has 174 institutional holders and institutional ownership of 86.4%.

Insider activity

Insiders reported 47 transactions (8 buys, 4 sells) across 12 reporting insiders, with a net reported value of $173.3K.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-04-30 (recurring since 2020-03-19) — source filing. The authoritative details are those stated in the filing itself.

Related companies

JANUX THERAPEUTICS INC (JANX) · THERAVANCE BIOPHARMA INC (TBPH) · EVOMMUNE INC (EVMN) · HARROW INC (HROW) · ARS PHARMACEUTICALS INC (SPRY) · SCHRODINGER INC (SDGR)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-20.